Cytokine Receptors and Signaling

  • Manzoor M. Khan


The biological effects of cytokines result after they interact with their highly specific cell surface receptors distributed on various tissues. The ligand–receptor interaction is quite limited to produce the biological responses since the number of cytokine receptors varies from as low as 10 2/cell to as high as 10 5/cell and the range for their affinity is about 10 10 M –1. The cytokine receptors are generally composed of multiple polypeptide chains, all of which may interact for the successful transmission of the cytokine-induced signal. There are five families of cytokine receptors, which include immunoglobulin superfamily receptors, class I cytokine receptor family (hematopoietin receptor family), class II cytokine receptor family (IFN receptor family), TNF receptor family and chemokine receptor family (Fig. 3.1).


Cytokine Receptor Janus Kinase Phosphotyrosine Residue Cytokine Receptor Family Tripeptide Motif 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Akira S. 2003. Toll-like receptor signaling. J Biol Chem. 278:38105–38108.PubMedCrossRefGoogle Scholar
  2. Alexander WS, Hilton DJ. 2004. The. role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Ann Rev Immunol. 22:503–529.CrossRefGoogle Scholar
  3. Bazan JF. 1990. Structural. design and molecular evolution of a cytokine receptor superfamily. Proc Nat Acad Sci. USA. 87:6934–6938.CrossRefGoogle Scholar
  4. Bonni A, Brunet A, West AE, Datta SR, et al. 1999. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and – independent mechanisms. Science. 286:1358–1362.PubMedCrossRefGoogle Scholar
  5. Bradley JR, Prober JS. 2001. Tumor necrosis factor receptor associated factors (TRAFs). Oncogene. 20:6482–6491.PubMedCrossRefGoogle Scholar
  6. Chadee DN, Yuasa T, Kyriakis JM. 2002. Direct activation of mitogen-activated protein kinase kinase kinase MEKK1 by the Ste20p homologue GCK and the adapter protein TRAF2. Mol Cell Biol. 22:737–749.Google Scholar
  7. Chang F, Steelman LS, Lee JT, Shelton JG, et al. 2003. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokines to transcription factors: potential targeting for therapeutic intervention. Leukemia. 17:1263–1293.PubMedCrossRefGoogle Scholar
  8. Chang L, Karin M. 2001. Mammalian MAP kinase signaling cascades. Nature. 410:37–40.PubMedCrossRefGoogle Scholar
  9. Chen G, Goeddel DV. 2002. TNF-R1 signaling: A beautiful pathway. Science. 296:1634–1635.PubMedCrossRefGoogle Scholar
  10. Chen W, Hershey GKK. 2007. Signal transducer and activator of transcription signals in allergic disease. J. Allergy Clin Immunol. 119:529–541.CrossRefGoogle Scholar
  11. Chen YR, Tan TH. 1999. Mammalian c-jun n-terminal kinase pathway and ste20-related kinases. Gene Ther Mol Biol. 4:83–98.Google Scholar
  12. Cosman D, Lyman SD, Idzerda RL, Beckmann MP. 1990. A new cytokine receptor superfamily. Trends Biochem Sci. 15:265–270.PubMedCrossRefGoogle Scholar
  13. Dai X, Chen Y, Di L, Podd A, et al. 2007. Stat5 is essential for early B cell development but not for B cell maturation and function. J Immunol. 179:1068–1079.PubMedGoogle Scholar
  14. D’Andrea AD. 1994. Cytokine receptors in congenital hematopoietic disease. NEJM. 330: 839–846.PubMedCrossRefGoogle Scholar
  15. deWeerd NA, Samarajiwa SA, Hertzog PJ. 2007. Type 1 interferon receptors: Biochemistry and biological functions. J Biol Chem. 282:20053–20057.CrossRefGoogle Scholar
  16. Egan PJ, Lawlor KE, Alexander PS, Wicks IP. 2003. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J Clin Inv. 111:915–924.Google Scholar
  17. Elkasmi KC, Holst J, Coffre M, Mielke C, et al. 2006. General nature of the STAT3-activated anti-inflammatory response. J Immunol. 177:7880–7888.Google Scholar
  18. Gadina M, Hilton D, Johnston JA, Morinobu A, et al. 2001. Signaling by type 1 and type II receptors: Ten years after. Curr Opin Immunol. 13:363–373.PubMedCrossRefGoogle Scholar
  19. Geijsen N, Koenderman L, Coffer PJ. 2001. Specificity in cytokine signal transduction: Lessons learned from the IL-3/IL-5/GM-CSF receptor family. Cytokine Growth Factor Rev. 12:19–25.PubMedCrossRefGoogle Scholar
  20. Haan C, Kreis S, Margue C, Behrmann I. 2006. JAKs and cytokine receptors – An intimate relationship. Biochem Pharmacol. 72:1538–1546.PubMedCrossRefGoogle Scholar
  21. Hazzalin CA, Mahadevan LC. 2002. MAPK-regulated transcription: A continuously variable gene switch? Nat Rev Mol Cell Biol. 3:30–40.PubMedCrossRefGoogle Scholar
  22. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. 1998. Interleukin-6 type cytokine signaling through the gp130/JAK/STAT pathway. Biochem J. 334:297–314.PubMedGoogle Scholar
  23. Hershey GK. 2003. IL-13 receptors and signaling pathways: An evolving web. J All Clin Immunol. 111:677–690.CrossRefGoogle Scholar
  24. Ihle JN. 1995. Cytokine receptor signaling. Nature. 377:591–594.PubMedCrossRefGoogle Scholar
  25. Ihle JN, Witthum BA, Quelle FW, Yamamoto K, et al. 1995. Signaling through the hematopoietic cytokine receptors. Ann Rev Immunol. 13:369–398.CrossRefGoogle Scholar
  26. Ivashkiv LB, Tassiulas I. 2003. Can SOCS make arthritis better? J Clin Inv. 111:795–797.Google Scholar
  27. Kato Y, Kravchenko VV, Tapping RI, Han J, et al. 1997. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 16:7054–7066.PubMedCrossRefGoogle Scholar
  28. Kiefer F, Tibbles LA, Anafi M, Janssen A, et al. 1996. HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway. EMBO J. 16:7013–7025.Google Scholar
  29. Kondo M, Takeshita T, Ishii N, Nakamura M, et al. 1993. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science. 262:1874–1877.PubMedCrossRefGoogle Scholar
  30. Koziczak-Holbro M, Joyce C, Gluk A, Kinzel B, et al. 2007. IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- and toll-like receptor-7 mediated signaling and gene expression. J Biol Chem. 282:13552–13560.PubMedCrossRefGoogle Scholar
  31. Krebs DL, Hilton DJ. 2001. SOCS proteins: Negative regulators of cytokine signaling. Stem Cells. 19:378–387.PubMedCrossRefGoogle Scholar
  32. Kubo M, Hanada T, Yoshimura A. 2003. Suppressors of cytokine signaling and immunity. Nat Immunol. 4:1169–1176.PubMedCrossRefGoogle Scholar
  33. Levy DE, Lee C. 2003. What does STAT3 do? J Clin Inv. 109:1143–1148.Google Scholar
  34. Li Y, shen BF, Karanes C, Sensenbrenner L, Chen B. 1995. Association between Lyn protein tyrosine kinase (p53/56 lyn) and the beta subunit of the granulocyte-macrophage colony-stimulating factor (GM-CSF) recepto9rs in a GM-CSF-dependent human megakaryocytic leukemia cell line (M-07e). J Immunol. 155:2165–2174.Google Scholar
  35. Locksley RM, Killeen N, Lenardo MJ. 2001. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell. 104:487–501.PubMedCrossRefGoogle Scholar
  36. Lynch RA, Etchin J, Battle TE, Frank DA. 2007. A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-γ in human cancer cells. Cancer Res. 67:1254–1261.PubMedCrossRefGoogle Scholar
  37. Martinez-Moczygemba M, Huston DP. 2003. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J All Clin Immunol. 112:653–665.CrossRefGoogle Scholar
  38. Miyajima A, Kitamura T, Harda N, Yokota T, et al. 1992. Cytokine receptors and signal transduction. Ann Rev Immunol. 10:295–331.CrossRefGoogle Scholar
  39. Moore KW, de-Waal R, Coffman RL, O’Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol. 19:683–765.Google Scholar
  40. Murray PJ. 2007. The JAK-STAT signaling pathway: Input and output integration. J Immunol. 178:2623–2629.PubMedGoogle Scholar
  41. Ogata N, Kouro T, Yamada A, Koike M, et al. 1998. JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor alpha and betac subunit, respectively, and are activated upon IL-5 stimulation. Blood. 91:2264–2271.PubMedGoogle Scholar
  42. Olosz F, Malek TR. 2002. Structural basis for binding multiple ligands by the common cytokine receptor gamma-chain. J Biol Chem. 277:12047–12055.PubMedCrossRefGoogle Scholar
  43. O’Neill LA. 2002. Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfamily. Curr Top Microbiol Immunol. 270:47–61.PubMedCrossRefGoogle Scholar
  44. O’Sullivan LA, Liongue C, Lewis RS, Stephenson SE, et al. 2007. Cytokine receptor signaling through the JAK-stat-socs pathway in disease. Mol Immunol. 44:2497–2506.PubMedCrossRefGoogle Scholar
  45. Pearson G, English JM, White MA, Cobb MH. 2001a. ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation. J Biol Chem. 276:7927–7931.CrossRefGoogle Scholar
  46. Pearson G, Robinson F, Gibson TB, Xu BE, et al. 2001b. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocrine Rev. 22:153–183.CrossRefGoogle Scholar
  47. Pestka S, Krause CD, Sarkar D, Walter MR. 2004. Interleukin-10 and related cytokines and receptors. Ann Rev Immunol. 22:929–979.CrossRefGoogle Scholar
  48. Quelle FW, Sato N, Witthuhn BA, Inhorn RC, et al. 1994. JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell biol. 14:4335–4341.PubMedGoogle Scholar
  49. Radtke S, Haan S, Jorissen A, Hermanns HM, et al. 2005. The JAK1 SH2 domain does not fulfill a classical SH2 function in JAK/STAT signaling but plays a role for receptor interaction and up-regulation of receptor surface expression. J Biol Chem. 280:25760–25768.PubMedCrossRefGoogle Scholar
  50. Ramana CV, Gil MP, Schreiber RD, Stark GR. 2002. STAT-1-dependent and – independent pathways in IFN-γ-dependent signaling. Trends Immunol. 23:96–101.PubMedCrossRefGoogle Scholar
  51. Ransohoff RM. 1998. Cellular responses to interferons and other cytokines: The JAK-STAT paradigm. NEJM. 338:616–168.PubMedCrossRefGoogle Scholar
  52. Rawlings JS, Rosler KM, Harrison DA. 2004. The JAK/STAT signaling pathway. J Cell Sci. 117:1281–1283.PubMedCrossRefGoogle Scholar
  53. Regis G, Conti L, Boselli D, Novelli F. 2006. IFN gamma R2 trafficking tunes IFN gamma-STAT1 signaling in T lymphocytes. Trends Immunol. 27:96–101.PubMedCrossRefGoogle Scholar
  54. Renauld JC. 2003. Class II cytokine receptors and their ligands, key antiviral and inflammatory modulators. Nat Rev Immunol. 3:667–676.PubMedCrossRefGoogle Scholar
  55. Rincon M, Pedraza-Alva G. 2003. JNK and P38 MAP kinases in CD4+ and CD8+ T cells. Immunol Rev. 192:131–142.PubMedCrossRefGoogle Scholar
  56. Roberts AW, Robb L, Rakar S, Hartley L, et al. 2001. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. PNAS. 98:9324–9329.PubMedCrossRefGoogle Scholar
  57. Sato N, Sakamaki K, Terada N, Arai K, Miyajima A. 1993. Signal transduction by the high-affinity GM-CSF receptor: Two distinct cytoplasmic regions of the common beta subunit responsible for different signaling. EMBO J. 12:4181–4189.PubMedGoogle Scholar
  58. Schmidt C, Peng G, Li Z, Sclabas GM, et al. 2003. Mechanisms of proinflammatory cytokine-induced biphasic NF-KB activation. Mol Cell. 12:1287–1300.PubMedCrossRefGoogle Scholar
  59. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2003. Interferon-γ, an overview of signals, mechanisms and functions. J Leukocyte Biol. 75:163–189.PubMedCrossRefGoogle Scholar
  60. Sharrocks AD. 2006. PIAS proteins and transcriptional regulation – More than just SUMOE3 ligases. Genes Dev. 20:754–758.PubMedCrossRefGoogle Scholar
  61. Shelburne CP, McCoy ME, Piekorz R, Sexl VV, et al. 2002. STAT5: An essential regulatory of mast cell biology. Mol Immunol. 38:1187–1191.PubMedCrossRefGoogle Scholar
  62. Shuai K, Liu B. 2003. Regulation of JAK-STAT signaling in the immune system. Nat Rev Immunol. 3:900–911.PubMedCrossRefGoogle Scholar
  63. Shuai K. 2006. Regulation of cytokine signaling pathways by PIAs proteins. Cell Res. 16: 196–202.PubMedCrossRefGoogle Scholar
  64. Sims JE. 2002. IL-1 and Il-18 receptors, and their extended family. Curr Opin Immunol. 14: 117–122.PubMedCrossRefGoogle Scholar
  65. Stephanou A, Latchman DS. 2005. Opposing actions of STAT-1 and STAT-3. Growth. Factors. 23:177–182.PubMedCrossRefGoogle Scholar
  66. Symons A, Beinke S, Ley SC. 2006. MAP kinase kinase kinases and innate immunity. Trends Immunol. 27:40–48.PubMedCrossRefGoogle Scholar
  67. Takaki S, Kanazawa H, Shiiba M, Takatsu K. 1994. A critical cytoplasmic domain of the interleukin-5 (IL-5) receptor alpha chain and its function in IL-5-mediated growth signal transduction. Mol Cell Biol. 14:7404–7413.PubMedGoogle Scholar
  68. Takaoka A, Hayakawa S, Yanai H, Stoiber D, et al. 2003. Integration of interferon-alpha/beta signaling to p53 responses in tumour suppression and antiviral defence. Nature. 424:516–523.PubMedCrossRefGoogle Scholar
  69. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. 2001. IRS family of transcription factors as regulators of host defense. Ann Rev Immunol. 19:623–655.CrossRefGoogle Scholar
  70. Taniguchi T, Takaoka A. 2002. The interferon-alpha/beta system in antiviral responses: A multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol. 14:111–116.PubMedCrossRefGoogle Scholar
  71. Tavernier J, Devos R, Cornelis S, Tuypens T, et al. 1991. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell. 66:1175–1184.PubMedCrossRefGoogle Scholar
  72. Torii S, Nakayama K, Yamamoto T, Nishida E. 2004. Regulatory mechanisms and function of ERK MAP kinases. J Biochem. 136:557–561.PubMedCrossRefGoogle Scholar
  73. Wajant H, Henkler F, Scheurich P. 2001. The TNF receptor-associated factor family: Scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal. 13:389–400.PubMedCrossRefGoogle Scholar
  74. Wajant H, Pfizenmaier K, Scheurich P. 2003. Tumor necrosis factor signaling. Cell Death Differ. 10:45–65.PubMedCrossRefGoogle Scholar
  75. Waldmann T, Tagaya Y, Bamford R. 1998. Interleukin 2, interleukin 15 and their receptors. Int Rev Immunol. 16:205–226.PubMedCrossRefGoogle Scholar
  76. Watford WT, Hissong BD, Kannu JH, Muul L, O’Shea JJ. 2004. Signaling by IL-12 and IL-23 and the immunoregulatory role of STAT4. Immunol. Rev. 202:139–156.PubMedCrossRefGoogle Scholar
  77. Weston CR, Lambright DG, Davis RJ. 2002. Signal transduction. MAP kinase signaling specificity. Science. 296:2345–2347.PubMedCrossRefGoogle Scholar
  78. Wong PKK, Egan PJ, Croker BA, Donnell KO, et al. 2004. SOCS3 negatively regulates innate and adaptive immune mechanism in acute IL-1-dependent inflammatory arthritis. J Clin Inv. 116:1571–1581.CrossRefGoogle Scholar
  79. Yeh TC, Pellegrini S. 1999. The Janus Kinase family of protein tyrosine kinase and their ole in signaling. Cell Mol Life Sci. 55:1523–1534.CrossRefGoogle Scholar
  80. Yu Q, Thieu VT, Kaplan MH. 2007. STAT4 limits DNA methyltransferase recruitment and DNA methylation of the IL-18Rα gene during TH1 differentiation. The EMBO J. 26:2052–2060.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Creighton University Medical CenterOmahaUSA

Personalised recommendations